Anzeige
Mehr »
Montag, 30.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
314 Leser
Artikel bewerten:
(1)

MJ Biotech, Inc.: MJ Biotech Offers Covid-19 FDA Approved Nasopharyngeal Specimen Collection Swabs RT-PCR COVID Test Kit

CHEYENNE, WY / ACCESSWIRE / February 24, 2021 / MJ Biotech, Inc. (OTC PINK:MJTV), is pleased to report that Sterile and individually wrapped FDA approved nasopharyngeal (nasal) specimen collection swabs for the RT-PCR COVID test was added to the COVID -19 product line. This Covid-19 test (inclusive of the swabs to the RT-PCR test) is in addition to the Covid-19 IgG/IgM Antibody Rapid Test Kits already being offered by MJ Biotech, Inc. Sales representative, Invest Africa Global, LLC (IAG) asked MJTV to add this to the product offering at the request of IAG's customers.

MJ Biotech Shipped out Samples of this RT-PCR Covid-19 Test last week to IAG customers. The RT-PCR Covid-19 Test and Covid-19 IgG/IgM Antibody Test now gives the IAG buyers the flexibility, to either test individuals for the active Covid-19 or the Covid-19 Antibodies.

The logistics of the first order from delivery to payment are currently being worked on. After the first transaction is completed, a seamless process will be in place to handle subsequent new and repeating transactions.

IAG is representing MJ Biotech, Inc. in multiple jurisdictions on the African Continent. They have secured several potential business opportunities for the Covid-19 Antibody Test Kit and now the Nasopharyngeal specimen collection swabs and RT-PCR COVID test.

A deeper and enhanced Scientific viewpoint of the RT-PCR Covid-19 Test Product:

The Coronavirus (Covid-19) specimen collection swabs are suitable for collecting both nasopharyngeal (NP) or oropharyngeal (OP) Covid-19 contaminated secretions. The testing swab consist of a flocked nylon fiber head (3mm x 16 mm), with a polypropylene handle that is 15.1 cm. The polypropylene handle has a molded break point at 8.2 cm, which easily fractures, for simple transport and placement into sterilized transport media.

The Covid-19 collection swabs are transported in a sterilized collection tube, secured with a twist on cap. The collected Covid-19 specimen test is then placed in a E -beam irradiation packaging. These strict and sterile conditions would prevent DNase, RNase, endotoxins, or cell inhibitors, potentially contaminating the Covid-19 specimen test sample. The Covid-19 collection swabs have a extraordinary water absorption capacity. This extraordinary water absorption will ensure high reliability of accurate Covid-19 test results.

For additional information please contact us at info@mjbiotech.us.

Safe Harbor Statement: Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. MJ Biotech Inc. does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated status of such statements. Therefore, in no case whatsoever will MJ Biotech. Inc. and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.

SOURCE: MJ Biotech, Inc.



View source version on accesswire.com:
https://www.accesswire.com/631547/MJ-Biotech-Offers-Covid-19-FDA-Approved-Nasopharyngeal-Specimen-Collection-Swabs-RT-PCR-COVID-Test-Kit

© 2021 ACCESS Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.